Job Description

Contractor (6 Months): high-throughput cellular assays



Location: Basel



Monte Rosa Therapeutics is seeking a contractor (initial 6 months) with experience in implementing and running complex cellular assays. This position is a key role in the pivotal team responsible for Automation and screening technologies, as well as hits-to-leads support for Monte Rosa's diverse pipeline. The ideal candidate will be able to help evolve Monte Rosa's hit identification and hits-to-leads endeavors through embracing novel assay technologies, enhancing overall processes, and actively driving internal and external partnerships.



Principal Duties and Responsibilities:



Perform a variety of molecular and cellular biology techniques, including CRISPR knock-in, mammalian cell culture, DNA/RNA isolation, and Western blotting

Implement and help to execute cell-based assays using various technologies (e.g., fluorescence, luminescence, TR-FRET, AlphaScreen)

Utilize automated liquid handling systems and laboratory robotics

Analyze and interpret experimental data, compile results, and present findings to the team

Maintain cell lines and prepare stock solutions

Manage laboratory inventories and handle biohazardous materials according to safety protocols

Ensure compliance with laboratory safety procedures and guidelines

Qualifications:



Minimum bachelor's degree or equivalent in Biochemistry, Cell Biology, or life science with at least 1-2 years of industrial experience.

Experience in High Throughput Screenings and Cellular assays for compound profiling is essential.

Experience with mammalian cell culture and cell line generation. CRISPR experience is highly considered.
Knowledge of Genedata software package is preferred.

Proven track record for striving for a high level of innovation and scientific excellence.




Interested Candidates may forward a CV and Cover Letter in a single PDF via our online portal https://www.monterosatx.com/careers/





Monte Rosa Therapeutics is a clinical-stage biotechnology company developing highly selective molecular glue degrader (MGD) medicines for patients living with serious diseases in the areas of oncology, autoimmune and inflammatory diseases, and more. MGDs are small-molecule protein degraders that have the potential to treat many diseases that other modalities, including other degraders, cannot. Monte Rosa's QuEEN(TM) (Quantitative and Engineered Elimination of Neosubstrates) discovery engine combines AI-guided chemistry, diverse chemical libraries, structural biology, and proteomics to rationally design MGDs with unprecedented selectivity. Monte Rosa has developed the industry's leading pipeline of MGDs, which spans autoimmune and inflammatory diseases, oncology, and beyond. Monte Rosa has a global license agreement with Novartis to advance VAV1-directed molecular glue degraders and a strategic collaboration with Roche to discover and develop MGDs against targets in cancer and neurological diseases previously considered impossible to drug. For more information, visit www.monterosatx.com.

Company

Monte Rosa Therapeutics AG

Location

Basel, Switzerland

Categories

Therapeutics/vaccines (human)

Type of job

Research

Contact information

HR


careers-basel@monterosatx.com